332 related articles for article (PubMed ID: 30682661)
21. Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies.
Gorgannezhad L; Umer M; Islam MN; Nguyen NT; Shiddiky MJA
Lab Chip; 2018 Apr; 18(8):1174-1196. PubMed ID: 29569666
[TBL] [Abstract][Full Text] [Related]
22. Potential of Liquid Biopsies for Breast Cancer Screening, Diagnosis, and Response to Treatment.
Eigeliene N; Saarenheimo J; Jekunen A
Oncology; 2019; 96(3):115-124. PubMed ID: 30654364
[TBL] [Abstract][Full Text] [Related]
23. Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.
Vymetalkova V; Cervena K; Bartu L; Vodicka P
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373199
[TBL] [Abstract][Full Text] [Related]
24. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
Hicks JK; Saller J; Wang E; Boyle T; Gray JE
Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
[TBL] [Abstract][Full Text] [Related]
25. Potential of circulating biomarkers in liquid biopsy diagnostics.
Yeo JC; Lim CT
Biotechniques; 2018 Oct; 65(4):187-189. PubMed ID: 30284936
[No Abstract] [Full Text] [Related]
26. Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC).
Gerratana L; Zhang Q; Shah AN; Davis AA; Zhang Y; Wehbe F; Qiang W; Flaum L; Finkelman BS; Gradishar WJ; Platanias LC; Behdad A; Cristofanilli M
Crit Rev Oncol Hematol; 2020 Jan; 145():102856. PubMed ID: 31884205
[TBL] [Abstract][Full Text] [Related]
27. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
28. Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?
Pi C; Zhang MF; Peng XX; Zhang YC; Xu CR; Zhou Q
Expert Rev Mol Diagn; 2017 Dec; 17(12):1089-1096. PubMed ID: 29057681
[TBL] [Abstract][Full Text] [Related]
29. Liquid Biopsy: General Concepts.
Poulet G; Massias J; Taly V
Acta Cytol; 2019; 63(6):449-455. PubMed ID: 31091522
[TBL] [Abstract][Full Text] [Related]
30. Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer.
Freitas AJA; Causin RL; Varuzza MB; Calfa S; Hidalgo Filho CMT; Komoto TT; Souza CP; Marques MMC
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077348
[TBL] [Abstract][Full Text] [Related]
31. Cell free circulating tumor nucleic acids, a revolution in personalized cancer medicine.
Kerachian MA; Poudineh A; Thiery JP
Crit Rev Oncol Hematol; 2019 Dec; 144():102827. PubMed ID: 31715326
[TBL] [Abstract][Full Text] [Related]
32. Review ctDNA and Breast Cancer.
Clatot F
Recent Results Cancer Res; 2020; 215():231-252. PubMed ID: 31605232
[TBL] [Abstract][Full Text] [Related]
33. Liquid Biopsy: Approaches to Dynamic Genotyping in Cancer.
von Bubnoff N
Oncol Res Treat; 2017; 40(7-8):409-416. PubMed ID: 28693026
[TBL] [Abstract][Full Text] [Related]
34. Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations: Techniques and Challenges.
Rodda AE; Parker BJ; Spencer A; Corrie SR
ACS Sens; 2018 Mar; 3(3):540-560. PubMed ID: 29441780
[TBL] [Abstract][Full Text] [Related]
35. [Circulating Tumor DNA (ctDNA) Detection Using BEAMing and Its Clinical Significance.].
Nakamura K
Rinsho Byori; 2016 May; 64(4):400-406. PubMed ID: 29182806
[TBL] [Abstract][Full Text] [Related]
36. Implementing circulating tumor DNA analysis in a clinical laboratory: A user manual.
Koessler T; Addeo A; Nouspikel T
Adv Clin Chem; 2019; 89():131-188. PubMed ID: 30797468
[TBL] [Abstract][Full Text] [Related]
37. Liquid biopsy for cancer screening, diagnosis, and treatment.
Smania MA
J Am Assoc Nurse Pract; 2020 Jan; 32(1):5-7. PubMed ID: 31913212
[TBL] [Abstract][Full Text] [Related]
38. A Study of Pre-Analytical Variables and Optimization of Extraction Method for Circulating Tumor DNA Measurements by Digital Droplet PCR.
Cavallone L; Aldamry M; Lafleur J; Lan C; Gonzalez Ginestet P; Alirezaie N; Ferrario C; Aguilar-Mahecha A; Basik M
Cancer Epidemiol Biomarkers Prev; 2019 May; 28(5):909-916. PubMed ID: 30824523
[TBL] [Abstract][Full Text] [Related]
39. A nanoflow cytometric strategy for sensitive ctDNA detection via magnetic separation and DNA self-assembly.
Zhai X; Li J; Cao Y; Zhu X; Tang Y; Chen G; Han K
Anal Bioanal Chem; 2019 Sep; 411(23):6039-6047. PubMed ID: 31304564
[TBL] [Abstract][Full Text] [Related]
40. Circulating tumor DNA - Current state of play and future perspectives.
De Rubis G; Krishnan SR; Bebawy M
Pharmacol Res; 2018 Oct; 136():35-44. PubMed ID: 30142423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
